Effect and Influence of Sacubitril Valsartan Sodium and Bisoprolol in the Treatment of Hypertensive Patients with Heart Failure
Objective To explore the efficacy and safety of sacubitril valsartan sodium and bisoprolol in the treatment of hypertension combined with heart failure.Methods A total of 108 hypertensive patients with heart failure admitted to Wuzhi County People's Hospital from January 2022 to January 2023 were divided into control group and study group using the opaque envelope method,with 54 cases in each group.The control group was treated with bisoprolol,while the study group was treated with bisoprolol + sacubitril valsartan sodium.The therapeutic effects,adverse reactions,cardiac function[left ventricular end diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),interventricular septal thickness(IVST)],blood pressure[diastolic blood pressure(DBP),systolic blood pressure(SBP)],hemorheological indicators[erythrocyte electrophoresis time(EET),hematocrit(HCT),erythrocyte sedimentation rate(ESR),plasma viscosity(PV)],and disease-related factors[cardiotrophin-1(CT-1),intercellular cell adhesion molecule-1(ICAM-1),N-terminal brain natriuretic peptide(NT-proBNP)]levels between two groups were compared.Results The effective rate of treatment in the study group(94.44%)was higher than that in the control group(77.78%),and the difference was statistically significant(P＜0.05);After treatment,the DBP,SBP,LVEDD,and IVST in the study group were lower than those in the control group,and LVEF was higher than that in the control group,with statistical significance(P＜0.05);After treatment,the HCT,ESR,EET,and PV of the study group were lower than those of the control group,and the differences were statistically significant(P＜0.05);After treatment,the CT-1,ICAM-1,and NT-proBNP levels in the study group were lower than those in the control group,and the differences were statistically significant(P＜0.05);There was no statistically significant difference in the incidence of adverse reactions between the study group(11.11%)and the control group(7.41%)(P＞0.05).Conclusion The combination of sacubitril and valsartan sodium with bisoprolol is more effective than bisoprolol monotherapy in the treatment of hypertension combined with heart failure.It can improve hemorheological indicators,delay ventricular remodeling and heart failure,promote heart function recovery,and is safer and more reliable.
sacubitril valsartan sodiumhypertensionheart failurebisoprololcardiac function
万方数据
维普
